IsoPlexis

Data-driven and highly-targeted immunotherapies are the future of the fight against cancer. IsoPlexis, develops novel solutions that are accelerating the revolution in immune and cell-based treatments of cancer. The Isolight, a next-generation analytics platform, profiles responses at the single-cell level enabling researchers to generate a precise functional patient signature to help predict and understand complex response to cancer immunotherapies. Isoplexis has partnered with leading biopharmaceutical companies and trial centers to generate real-world data to advance high-need areas of cell product characterization, immune biomarker discovery, and patient monitoring.

www.isoplexis.com